Li-Chuan Chan
Impact in
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
- Oncology 23
- Cancer Immunotherapy and Biomarkers 11
- PARP inhibition in cancer therapy 6
- Cancer Cells and Metastasis 6
- Immunology 14
- Immunotherapy and Immune Responses 9
- Immune Cell Function and Interaction 4
- Co-authors
- Mien‐Chie Hung (20 shared papers)Jennifer L. Hsu (17 shared papers)Jong‐Ho Cha (5 shared papers)Chia‐Wei Li (5 shared papers)Jung-Mao Hsu (11 shared papers)Weiya Xia (8 shared papers)Yongkun Wei (7 shared papers)Linlin Sun (6 shared papers)
- Journals
- Nature Communications (4 papers)Cancer Research (4 papers)Cancer Cell (2 papers)Journal of Clinical Investigation (2 papers)International Journal of Biological Sciences (2 papers)
- Partner nations
- United StatesTaiwanChina
In The Last Decade
Li-Chuan Chan
40 papers receiving 6.5k citations
Li-Chuan Chan's Hit Papers
Peers
Comparison fields: 5 of 111
- Oncology 3.1k
- Immunology 2.3k
- Cancer Research 1.1k
- Molecular Biology 2.8k
- Pulmonary and Respiratory Medicine 740
Countries citing papers authored by Li-Chuan Chan
This map shows the geographic impact of Li-Chuan Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li-Chuan Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li-Chuan Chan more than expected).
Fields of papers citing papers by Li-Chuan Chan
This network shows the impact of papers produced by Li-Chuan Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li-Chuan Chan. The network helps show where Li-Chuan Chan may publish in the future.
Co-authors
The 25 scholars most cited alongside Li-Chuan Chan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity Hit paper breakdown → | 2016 | 902 |
| 2 | Mechanisms Controlling PD-L1 Expression in Cancer Hit paper breakdown → | 2019 | 823 |
| 3 | Deubiquitination and Stabilization of PD-L1 by CSN5 Hit paper breakdown → | 2016 | 676 |
| 4 | Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1 Hit paper breakdown → | 2018 | 665 |
| 5 | Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1 Hit paper breakdown → | 2018 | 492 |
| 6 | Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth Hit paper breakdown → | 2018 | 446 |
| 7 | 2018 | 376 | |
| 8 | 2019 | 312 | |
| 9 | 2019 | 279 | |
| 10 | TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis Hit paper breakdown → | 2021 | 276 |
| 11 | 2018 | 237 | |
| 12 | 2020 | 143 | |
| 13 | 2022 | 129 | |
| 14 | Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. | 2018 | 108 |
| 15 | 2019 | 78 | |
| 16 | Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. | 2018 | 63 |
| 17 | 2014 | 63 | |
| 18 | 2011 | 44 | |
| 19 | 2022 | 43 | |
| 20 | Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. | 2015 | 42 |
About Li-Chuan Chan
Li-Chuan Chan is a scholar working on Oncology, Immunology, Molecular Biology, Biotechnology and Pulmonary and Respiratory Medicine, having authored 40 papers that have together received 6.6k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (11 papers), Immunotherapy and Immune Responses (9 papers), PARP inhibition in cancer therapy (6 papers), Cancer Cells and Metastasis (6 papers), DNA Repair Mechanisms (4 papers), Immune Cell Function and Interaction (4 papers), Glycosylation and Glycoproteins Research (3 papers) and Cancer Research and Treatments (3 papers). The work is most often cited by research in Oncology (3.1k citations), Immunology (2.3k citations), Cancer Research (1.1k citations), Molecular Biology (2.8k citations) and Pulmonary and Respiratory Medicine (740 citations). Li-Chuan Chan has collaborated with scholars based in United States, Taiwan and China. Frequent co-authors include Mien‐Chie Hung, Jennifer L. Hsu, Jong‐Ho Cha, Chia‐Wei Li, Jung-Mao Hsu, Weiya Xia, Yongkun Wei, Linlin Sun, Junwei Hou and Yi Yang. Their work appears in journals such as Nature Communications, Cancer Research, Cancer Cell, Journal of Clinical Investigation and International Journal of Biological Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.